Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

This publication has 23 references indexed in Scilit:

• Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab
  Bone Marrow Transplantation, 2001
• The immunosuppressive macrolide RAD inhibits growth of human Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo : A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
  Proceedings of the National Academy of Sciences, 2000
• TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH THE ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB ALONE IN AN ADULT AFTER LIVER TRANSPLANTATION
  Transplantation, 2000
• Treatment of lympho-proliferative disease with rituximab
  The Lancet, 2000
• Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab
  Leukemia & Lymphoma, 2000
• Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
  The Lancet, 1999
• EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
  Transplantation, 1999
• Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
  The Lancet, 1998
• Dominant Mutations Confer Resistance to the Immunosuppressant, Rapamycin, in Variants of a T Cell Lymphoma
  Cellular Immunology, 1995
• Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation
  New England Journal of Medicine, 1991